Instruction for use: Apo-Bromocriptine

Dosage form: Tablets

Active substance: Bromocriptine*

ATX

N04BC01 Bromocriptine

Pharmacological groups:

Dopaminomimetics

Anti-Parkinsonics

Composition and release form

1 tablet contains bromocriptine monosulfonate 2.5 mg, in vials of 100, 500 or 1000 pcs.

Pharmachologic effect

Dopaminomimetic, antiparkinsonian, reduced secretion of prolactin, reduction of hypersecretion of growth hormone, reduction in the size and number of cysts in the mammary gland.

Pharmacokinetics

After oral administration, it is quickly absorbed (about 65-95%), the half-absorption period is 20 min. As a result of the first passage through the liver, only 7% of the dose enters the blood in unchanged form. T1 / 2 after a single admission is 2-8 hours (50-70 h for metabolites). Excretion is through the liver, about 6% through the kidneys.

Indications for Apo-Bromocriptine

Prolactin-dependent disorder of menstrual function and infertility; Prolactin-dependent hypogonadism in men, hyperprolactinaemia in men; acromegaly; Prolactinoma; Suppression of lactation in benign breast diseases; Parkinson's disease, symptomatic parkinsonism.

Contraindications

Hypersensitivity, arterial hypertension, toxicosis of pregnant women.

Application in pregnancy and breastfeeding

Not recommended. An exception is made when the possible positive effect of treatment outweighs the potential risk to the fetus.

Side effects

Nausea, vomiting, dizziness, orthostatic hypotension (rarely), drowsiness, headache, psychomotor agitation, hallucinations, dry mouth, constipation, allergic reactions.

Interaction

Macrolides increase the concentration in the blood. It should not be combined with drugs that have a vasoconstrictive effect, as well as with derivatives of ergot alkaloids. Domperidone (a dopamine antagonist) reduces effectiveness. Perhaps excessive reduction in blood pressure while taking other antihypertensive drugs. Incompatible with alcohol.

Dosing and Administration

Inside with food. With galactorrhea, amenorrhea, infertility against the background of hyperprolactinaemia, prolactin-dependent hypogonadism in men, the initial dose is 1.25-2.5 mg at bedtime, with an increase in 2-3 days to 2.5 mg 2 or 3 times. To prevent or suppress postpartum lactation - 2.5 mg 2 times (during morning and evening meals) per day for 2-3 weeks. With prolactinomas - 1.25 mg 2-3 times a day with a gradual increase to 5-7.5 mg per day (if necessary, up to 10-20 mg per day). With acromegaly, an increase in the dose from 1.25-2.5 mg at bedtime to 10-20 mg per day (for 2-4 weeks). The daily dose of 20 mg should be divided into 4 divided doses. Parkinson's disease - the initial dose of 1.25 mg before bed, followed by an increase in 2-3 days to 1.25 mg 2 times a day. If necessary, the dosage is increased every 2-4 weeks by 2.5 mg per day. The average effective dose is 10 mg per day and, as a rule, does not exceed 40 mg per day.

Overdose

Symptoms: headache, hallucinations, arterial hypotension. Treatment: for acute overdose, parenteral administration of metoclopramide is recommended.

Precautionary measures

To prevent nausea and vomiting at the beginning of treatment, it is advisable to prescribe antiemetics for an hour before taking the drug. Periodic monitoring of blood pressure is recommended, especially in the first days of treatment. In a number of patients, apobrismocriptine causes dizziness, which interferes with the performance of activities requiring a quick and accurate reaction (for example, driving a car). Treatment with apo-bromocriptine can cause an accelerated resumption of ovarian function after childbirth, in connection with which it is necessary to warn women about the possibility of early postpartum conception. When treated in large doses (parkinsonism), confusion may occur. It should be used with caution in patients with Parkinsonism with signs of dementia. It is recommended to periodically monitor liver and kidney function.

Storage conditions of the drug Apo-Bromocriptine

In the dark place.

Keep out of the reach of children.

Shelf life of the drug Apo-Bromocriptine

2 years.

Do not use after the expiry date printed on the package.